SOLICITATION NOTICE
65 -- Notice of Intent - Ortho Clinical Reagents and Supplies
- Notice Date
- 8/26/2024 9:17:22 AM
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH - CC BETHESDA MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- 24-012435
- Response Due
- 8/23/2024 9:00:00 AM
- Archive Date
- 09/07/2024
- Point of Contact
- Sheri Eiri, Phone: 000000000
- E-Mail Address
-
sheri.eiri@nih.gov
(sheri.eiri@nih.gov)
- Description
- Notice of Intent - Ortho Clinical Reagents and Supplies NAICS Code:������ 325413-In Vitro Diagnostic Substance Manufacturing (Small Business Size Standard 1,250 Average Number of Employees) PSC/FSC:� 6550-In Vitro Diagnostic Substances, Reagents, Test Kits and Sets Place of Performance: Bethesda, MD 20892 Previous POTS: 24-012435 Changed to�Updated POTS:�25-000043 Funding is currently not available for this requirement.� Description: This is a notice of intent, not a request for a quotation. A solicitation document will not be issued, and quotations will not be requested. The National Institutes of Health, Clinical Center, Office of Purchasing and Contracts on behalf of the Department of Transfusion Medicine intends to award a fixed price contract for twelve (12) months (one-year) to Ortho-Clinical Diagnostics, Inc., located at� 1001 US Highway 202, Raritan, New Jersey 08869-1424 on a sole source basis to supply analyzer supplies and reagents. The Department of Transfusion Medicine, Transfusion Services Laboratory provides blood products in support of transfusion therapy for patients being treated at the Clinical Center.� These blood products, per the Food and Drug Administration requirements, must be both safe and effective when treating patients.� To be safe and effective, the blood products must at least match or be compatible with the ABO/Rh of the patients, and in addition, be a match or compatible with extended antigen typing beyond ABO/Rh. �To accomplish this, specific Ortho Clinical reagents are required which will not only be used for testing of patients, but also for testing and compatibility testing of donors who provide the blood products. These reagents have been approved and have unique red cell antigen composition and the amount of red cell donors available per panel.� Large-scale validation studies have been performed to support the use of these reagents for clinical testing.� These reagents are the only compatible reagents to use with the Ortho Vision analyzer.� In addition, Ortho Clinical Diagnostics does not have any authorized third-party resellers or distributor of its products. �Use of a reagent from another source would require new validation studies, and thereby would delay clinical patient testing. This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 � Simplified Acquisition Procedures, Subpart 13.106-1(b)(1).� For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available.� Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Interested Parties: Interested parties capable of providing the same or similar products or services described in this notice may submit a capability statement outlining their capability to perform the described work.� Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. The determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Comments: Comments to this announcement, referencing this posting number, may be submitted to the CC, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Sheri Eiri, Contract Specialist, sheri.eiri.nih.gov by the due date August 23, 2024, and time marked in this notice.� No phone calls will be accepted.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/d00da21d86ed445f9e3793c7f520df9d/view)
- Place of Performance
- Address: Bethesda, MD 20892, USA
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN07186531-F 20240828/240826230126 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |